Name | Number of supported studies | Average coverage | |
---|---|---|---|
smooth muscle cell | 13 studies | 26% ± 11% | |
cardiac muscle cell | 6 studies | 52% ± 13% | |
type I pneumocyte | 6 studies | 22% ± 4% | |
adipocyte | 3 studies | 22% ± 6% | |
muscle cell | 3 studies | 32% ± 11% | |
megakaryocyte-erythroid progenitor cell | 3 studies | 45% ± 18% | |
pericyte | 3 studies | 19% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
heart | 3 studies | 25% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 96% | 962.37 | 236 / 245 | 96% | 4.84 | 482 / 502 |
lung | 93% | 672.36 | 539 / 578 | 82% | 4.45 | 952 / 1155 |
esophagus | 95% | 1450.70 | 1379 / 1445 | 78% | 2.72 | 143 / 183 |
uterus | 92% | 942.01 | 156 / 170 | 78% | 4.95 | 359 / 459 |
bladder | 95% | 1306.90 | 20 / 21 | 72% | 3.62 | 361 / 504 |
thymus | 70% | 288.53 | 459 / 653 | 96% | 8.62 | 582 / 605 |
stomach | 93% | 802.20 | 333 / 359 | 67% | 2.34 | 193 / 286 |
intestine | 74% | 1354.32 | 716 / 966 | 77% | 2.46 | 406 / 527 |
breast | 81% | 510.18 | 372 / 459 | 65% | 2.85 | 732 / 1118 |
adrenal gland | 71% | 387.02 | 184 / 258 | 67% | 2.04 | 154 / 230 |
skin | 38% | 416.33 | 687 / 1809 | 95% | 13.18 | 449 / 472 |
ovary | 48% | 205.65 | 86 / 180 | 69% | 2.79 | 297 / 430 |
brain | 38% | 156.31 | 997 / 2642 | 78% | 1.90 | 547 / 705 |
eye | 0% | 0 | 0 / 0 | 100% | 23.73 | 80 / 80 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.22 | 1 / 1 |
blood vessel | 100% | 2425.23 | 1333 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 1459.71 | 798 / 803 | 0% | 0 | 0 / 0 |
heart | 98% | 2868.39 | 840 / 861 | 0% | 0 | 0 / 0 |
pancreas | 8% | 26.43 | 25 / 328 | 83% | 2.70 | 147 / 178 |
kidney | 25% | 90.84 | 22 / 89 | 64% | 2.12 | 580 / 901 |
tonsil | 0% | 0 | 0 / 0 | 73% | 2.35 | 33 / 45 |
adipose | 71% | 480.56 | 858 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 52% | 2.25 | 15 / 29 |
liver | 1% | 4.21 | 3 / 226 | 21% | 1.06 | 85 / 406 |
spleen | 5% | 13.52 | 11 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 2% | 9.90 | 23 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030148 | Biological process | sphingolipid biosynthetic process |
GO_0042761 | Biological process | very long-chain fatty acid biosynthetic process |
GO_0030497 | Biological process | fatty acid elongation |
GO_0035338 | Biological process | long-chain fatty-acyl-CoA biosynthetic process |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005515 | Molecular function | protein binding |
GO_0018812 | Molecular function | 3-hydroxyacyl-CoA dehydratase activity |
GO_0102158 | Molecular function | very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase activity |
Gene name | HACD1 |
Protein name | Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1 (EC 4.2.1.134) (3-hydroxyacyl-CoA dehydratase 1) (HACD1) (Cementum-attachment protein) (CAP) (Protein-tyrosine phosphatase-like member A) Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase (EC 4.2.1.134) very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase (EC 4.2.1.134) Protein tyrosine phosphatase-like, member A variant 4 3-hydroxyacyl-CoA dehydratase 1 |
Synonyms | PTPLA |
Description | FUNCTION: [Isoform 1]: Catalyzes the third of the four reactions of the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of two carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. This enzyme catalyzes the dehydration of the 3-hydroxyacyl-CoA intermediate into trans-2,3-enoyl-CoA, within each cycle of fatty acid elongation. Thereby, it participates in the production of VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. .; FUNCTION: [Isoform 2]: In tooth development, may play a role in the recruitment and the differentiation of cells that contribute to cementum formation. May also bind hydroxyapatite and regulate its crystal nucleation to form cementum. . FUNCTION: Catalyzes the third of the four reactions of the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of two carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. This enzyme catalyzes the dehydration of the 3-hydroxyacyl-CoA intermediate into trans-2,3-enoyl-CoA, within each cycle of fatty acid elongation. Thereby, it participates to the production of VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. . |
Accessions | ENST00000466335.1 ENST00000326961.6 B0YJ83 B0YJ81 ENST00000361271.8 [B0YJ81-1] J3KS69 ENST00000498812.5 A6NP58 J3KT94 |